3994-46-5

Basic information

• Product Name: 1H-Pyrazol-1-amine
• Synonyms: 1H-Pyrazol-1-amine;N-aminopyrazole
• CAS NO: 3994-46-5
• Molecular Formula: C₃H₅N₃
• Molecular Weight: 83.0935
• Mol File: 3994-46-5.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 209.822°C at 760 mmHg
• Flash Point: 80.698°C
• Appearance: /
• Density: 1.299g/cm³
• Vapor Pressure: 0.199mmHg at 25°C
• Refractive Index: 1.63
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 1H-Pyrazol-1-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazol-1-amine(3994-46-5)
• EPA Substance Registry System: 1H-Pyrazol-1-amine(3994-46-5)

Safety Data

• Hazardous Substances Data: 3994-46-5(Hazardous Substances Data)

Usage

General Description

1H-Pyrazol-1-amine, also known as aminopyrazole, is an organic chemical compound with a structure based on the heterocyclic ring compound pyrazole, which has the molecular formula C3H5N3. It is most often used as a precursor or intermediary in the production of various pharmaceuticals, such as cinnoline derivatives, and in the development of new drugs. This substance may also be used in a variety of other chemicals or substance applications where its properties as an amine are useful or appropriate.

InChI:InChI=1/C3H5N3/c4-6-3-1-2-5-6/h1-3H,4H2

Upstream product

• 288-13-1 NH-pyrazole 
• 1192-21-8 5-Amino-1-methylpyrazole 
• 4313-57-9 2,5-dihydrotoluene 

Downstream Products

• 121433-34-9 1-<(5-nitrofurfurylidene)amino>pyrazole 
• 288-13-1 NH-pyrazole 
• 99214-49-0 Di-pyrazol-1-yl-diazene 
• 99214-48-9 Di-pyrazol-1-yl-diazene 
• 289-96-3 1,2,3-triazine 
• 114078-88-5 5-bromo-1,2,3-triazine 
• 114078-89-6 4,5-dibromotriazine 
• 122481-11-2 4-bromo-1-trityl-1H-pyrazole 
• 1225387-53-0 3⁽⁵⁾-aminopyrazole 
• 99939-13-6 1-(2-Propinylidenamino)-1H-pyrazol 
• 99939-12-5 1,1'-Azopyrazol 
• 137968-13-9 1-(Cyclohexylideneamino)pyrazole 
• 137968-15-1 1-<(p-Fluorobenzylidene)amino>pyrazole 
• 137968-14-0 1-benzylideneaminopyrazole 

Relevant articles and documents

CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE

Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R2 is a cyclic ether and X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Inverse electron demand diels-alder reactions of 1,2,3-triazines: Pronounced substituent effects on reactivity and cycloaddition scope

A systematic study of the inverse electron demand Diels-Alder reactions of 1,2,3-triazines is disclosed, including an examination of the impact of a C5 substituent. Such substituents were found to exhibit a remarkable impact on the cycloaddition reactivity of the 1,2,3-triazine without altering, and perhaps even enhancing, the intrinsic cycloaddition regioselectivity. The study revealed not only that the reactivity may be predictably modulated by a C5 substituent (R = CO2Me > Ph > H) but also that the impact is of a magnitude to convert 1,2,3-triazine (1) and its modest cycloaddition scope into a heterocyclic azadiene system with a reaction scope that portends extensive synthetic utility, expanding the range of participating dienophiles. Significantly, the studies define a now powerful additional heterocyclic azadiene, complementary to the isomeric 1,2,4-triazines and 1,3,5-triazines, capable of dependable participation in inverse electron demand Diels-Alder reactions, extending the number of complementary heterocyclic ring systems accessible with implementation of the methodology.

Inflammation modulators

Compounds, compositions and methods that are useful in the treatment of inflammatory, immunoregulatory, metabolic and cell proliferative conditions or diseases are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, metabolism and cell proliferation. The subject compounds contain quinoline or quinazoline rings.